Hopes pinned on hepatitis C “salvage” combos

Clinicians treating patients with hepatitis C who did not respond to first-line direct acting antivirals (DAA) treatment should delay re-treating if possible, until new “salvage” therapies arrive in Australia. This was the message delivered by infectious diseases and hepatitis specialist Associate Professor Mark Douglas at GESA’s Australian Gastroenterology Week 2017. The various DAA combinations now available on the PBS ...

Already a member?

Login to keep reading.

© 2021 the limbic